BACKGROUND The authors previously reported that inhaled xenon combined with hypothermia attenuates brain white
T hroughout Europe, the in-hospital mortality of successfully resuscitated out-of-hospital cardiac arrest (OHCA) patients ranges from 41% to 86% (1) (2) (3) . International guidelines for postresuscitation care recommend targeted temperature management with target temperatures between 32 C and 36 C (4,5).
Post-cardiac arrest syndrome is a complex combination of ischemic cerebral and myocardial injury combined with a reperfusion response leading to different combinations of multiorgan failure; it is responsible for significant morbidity and mortality as a consequence of whole-body ischemia (4) . Although ischemic brain injury is the leading cause for inhospital deaths after OHCA, myocardial dysfunction and circulatory failure account for most deaths during the first 3 days (6, 7) . In addition, the severity of myocardial injury affects both short-and long-term mortality (8) (9) (10) . Therefore, new strategies to attenuate the ischemic reperfusion myocardial injury leading to cardiomyocyte death after cardiac arrest are needed.
Earlier clinical studies in patients with and without cardiovascular disease have demonstrated that inhalation of the noble gas xenon may be cardioprotective by decreasing heart rate without affecting either cardiac conductance or contractility (11) (12) (13) . In animal models, xenon has provided cardioprotection by preand post-conditioning mechanisms (14, 15) . We have reported previously that xenon combined with hypothermia confers neuroprotection by attenuating the brain white matter injury more than hypothermia alone in comatose survivors of cardiac arrest (16) .
Inhaled xenon is feasible, well-tolerated, and safe in OHCA patients (17) . The purpose of this study was to evaluate the effect of xenon on myocardial damage in comatose survivors of OHCA. Patients were informed accordingly if they regained consciousness (16, 17) .
METHODS
The patients were allocated in a 1:1 ratio with random block sizes of 4, 6, and 8 to receive either therapeutic hypothermia treatment alone for 24 h (designated as the control group) or inhaled xenon (LENOXe, Air Liquide Medical, Düsseldorf, Germany)
in combination with hypothermia for 24 h (designated as the xenon group). The clinical investigators enrolled the patients, and after assent was received, randomization was performed with sealed computerrandomized envelopes followed by the assigned intervention. Due to practical and safety considerations, the personnel involved in the patient treatment could not be blinded. A mode of death was classified as neurological, cardiac, or multiorgan as described previously (16) . A local neurological prognostication consensus was used in decisions to withdraw life-sustaining treatment (16) .
In the Xe-HYPOTHECA trial, the primary hypothesis was that xenon would attenuate white matter injury after OHCA. We have previously published the feasibility and cardiac safety of inhaled xenon after OHCA, and the effect of inhaled xenon on cerebral white matter damage and on the clinical outcome at 6 months in comatose survivors of OHCA (16, 17) . The latter report also included the protocol of the Xe-HYPOTHECA trial. The effect of xenon on myocardial injury was a pre-defined secondary endpoint. cardiologists who were blinded to the intervention group. Acute kidney injury was diagnosed as previously described (16, 17 Table 2 .
The baseline characteristics of the 54 xenon and 54
control patients for whom we had troponin-T data did not differ between the groups ( Table 1) . The reasons
for missing troponin-T data are summarized in Online Table 6 ). Geometric mean (95% CI) of troponin-T was significantly higher in STEMI than in NSTEMI at each time point after baseline (Online Table 7 ).
The change over time of the levels of troponin-T differed between the xenon and the control groups ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor blocker; COPD ¼ chronic obstructive pulmonary disease; OHCA ¼ out-of-hospital cardiac arrest.
PREDICTIVE VALUE OF TROPONIN-T FOR MORTALITY AT
6 MONTHS. The adjusted absolute value of each time point after baseline and the incremental change from baseline to each of time point of troponin-T release had a significant predictive value for mortality at 6 months after the index event within the groups and in the whole population (Online Table 8 ). The association of troponin-T release on survival did not differ between the groups (for all time points in the group by troponin-T interaction p > 0.10).
INTRAVENOUS DRUGS AND SEDATION DEPTH.
Significantly less propofol was administered in the xenon group compared with the control group during the first 72 h ( Table 4) Values are n (%). A diagnosis of acute myocardial infarction was based on the latest recommendations (8). *Data are for 44 patients in the xenon group and for 47 patients in the control group due to missing data.
NSTEMI ¼ non-ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
Arola et al. HEMODYNAMIC PARAMETERS. The median (interquartile range) heart rate was significantly lower in the xenon group than in the control group during the first 72 h. The other pre-defined hemodynamic parameters did not differ between the groups during the first 24 or 72 h ( Table 4) . Table 4 and Online Table 9 ) in the 2 groups or within the whole population (correlation data not shown).
DISCUSSION
The main finding of this study was that among Values are median (interquartile range) or mean AE SD. The hemodynamic parameters were recorded in 2-min epochs in Turku and in 5-min epochs in Helsinki. *In the xenon group, 53 patients received norepinephrine during ICU stay.
CVP ¼ central venous pressure; ICU ¼ intensive care unit; MAP ¼ mean arterial pressure; SAP ¼ systolic arterial pressure. Moreover, phosphorylation of PKC Ɛ , Akt, and GSK-3 b
by xenon has been reported to inhibit Ca2þ-induced mitochondrial permeability transition pore opening, which is known to preserve mitochondrial function and prevent ischemic reperfusion injury and cell death (27) .
We also analyzed the predictive value of troponin-T for all-cause mortality at 6 months after OHCA to heart against a post-ischemic reperfusion injury by decreasing troponin-T release after coronary artery bypass surgery (31) (32) (33) (34) (35) . Despite the possible cardioprotective properties of propofol, there was no correlation between the administered dose and the troponin-T release within the groups in this study.
Therefore, it is unlikely that the administration of propofol use had any significant impact on the current results.
Xenon's heart rate-decreasing properties have been well documented (11, 13, 17, 28, 29) . In our study, the combination of xenon and hypothermia resulted in a significantly lower heart rate when compared with hypothermia alone, with this effect lasting at least up to 72 h after OHCA. Interestingly, a recent trial demonstrated that pronounced sinus bradycardia during hypothermia was associated with improved outcome, and it was proposed to represent an independent marker of favorable neurocognitive outcome (36) . Therefore, one could argue that xenon's ability to reduce the heart rate may have some beneficial clinical value in cardiac arrest patients.
However, this was not supported by the current results because no correlation could be detected between heart rate and troponin-T release. Xenon Lessens Myocardial Damage
